Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. This growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels, with coverage expected to reach approximately 145 million lives when a managed Medicare agreement takes effect Jan. 1, 2027.
The strong commercial performance of TONMYA is a critical milestone for Tonix, as it validates the company's ability to launch and scale a new treatment in a market with high unmet need. Fibromyalgia affects millions of patients, and TONMYA is the first new therapy approved for this condition in over 15 years, offering a differentiated option for patients and physicians. The rapid uptake in prescriptions and expanding payer coverage position TONMYA to become a significant revenue driver for the company.
Beyond TONMYA's commercial success, Tonix is advancing its clinical pipeline with a focus on CNS and immunology. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, a condition that affects a large patient population. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs highlight the company's strategic diversification and potential for future growth.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents, and management stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This runway provides the company with the financial stability to execute on its commercial and clinical objectives without immediate capital constraints.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. In addition to TONMYA, the company's CNS portfolio includes acute migraine products Zembrace SymTouch and Tosymra, as well as TNX-2900 for Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.
